| CAS NO: | 1715025-32-3 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| Molecular Weight: 578.42 Formula: C26H27BrF3N5O2 CAS No.: 1715025-32-3 SMILES: O=C(N[C@@H](C1=CC(F)=CC(Br)=C1)CNC)C2=CC=C(C3=NC([C@@H]4C[C@H](F)[C@@H](O)CC4)=CN=C3N)C=C2F | |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Technical Information | ERK-IN 1; ERK IN-1; ERK-IN-1 |
| Target | RAF; ERK1; ERK2 |
|---|---|
| In Vivo | ERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice[1]. Animal Model: Calu-6 NSCLC xenograft tumor models in mice[1]. Dosage: 50, 75 mg/kg. Administration: Orally either daily (qd) or every other day (q2d) for 27 days. Result: Significantly reduced the tumor volume. |
| References | [1]. WO2018051306A1 |
m.cnreagent.com